Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-004025-14
    Sponsor's Protocol Code Number:GS-US-380-1844
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2015-12-29
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2015-004025-14
    A.3Full title of the trial
    A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed
    Estudio fase 3, aleatorizado y doble ciego para evaluar la seguridad y eficacia del cambio de un régimen formado por dolutegravir y ABC/3TC, o una combinación de dosis fijas (CDF) de ABC/DTG/3TC, a una CDF de GS-9883/F/TAF en sujetos infectados por el VIH-1 con supresión virológica
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    This study will test an experimental drug called GS-9883/F/TAF (GS-9883/emtricitabine/tenofovir alafenamide) fixed dose combination (FDC) for the treatment of HIV-1 infection. The purpose of this study is to test the effectiveness of switching to GS-9883/F/TAF FDC versus continuing on DTG and ABC/3TC as the FDC ABC/DTG/3TC in HIV-1 infected adults who are virologically suppressed (HIV-1 RNA test <50 copies/mL)
    Este estudio prueba el fármaco experimental GS- 9883/emtricitabina/tenofovir alafenamida (GS-9883/F/TAF) en combinación de dosis fija (CDF) para el tratamiento de infección por VIH-1. Su proposito es probar la efectividad de cambiar a GS-9883/F/TAF FDC frente a continuar con DTG y seguridad y ABC/3TC como CDF FDC ABC/DTG/3TC en adultos infectados por VIH-1 que están suprimidos virológicamente (prueba de ARN de VIH-1 <50 copias / ml)
    A.4.1Sponsor's protocol code numberGS-US-380-1844
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorGilead Science, Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGilead Sciences, Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationGilead Sciences International Ltd.
    B.5.2Functional name of contact pointClinical Trials Mailbox
    B.5.3 Address:
    B.5.3.1Street AddressFlowers Building, Granta Park
    B.5.3.2Town/ cityAbington, Cambridge
    B.5.3.3Post codeCB21 6GT
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number+34913789830
    B.5.6E-mailclinical.trials@gilead.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code GS-9883/F/TAF
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNGS-9883
    D.3.9.2Current sponsor codeGS-9883
    D.3.9.4EV Substance CodeSUB179805
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEMTRICITABINE
    D.3.9.1CAS number 143491-57-0
    D.3.9.4EV Substance CodeSUB01882MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTenofovir alafenamide
    D.3.9.1CAS number 379270-37-8
    D.3.9.3Other descriptive nameTENOFOVIR ALAFENAMIDE
    D.3.9.4EV Substance CodeSUB121761
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Triumeq
    D.2.1.1.2Name of the Marketing Authorisation holderViiV Healthcare UK Limited
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDolutegravir
    D.3.9.3Other descriptive nameDOLUTEGRAVIR
    D.3.9.4EV Substance CodeSUB35122
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNABACAVIR
    D.3.9.1CAS number 136470-78-5
    D.3.9.4EV Substance CodeSUB07356MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number600
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLAMIVUDINE
    D.3.9.1CAS number 134678-17-4
    D.3.9.4EV Substance CodeSUB08392MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number300
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Human Immunodeficiency Virus (HIV-1) Infection
    Infección por el Virus de Inmunodeficiencia Humana (VIH-1)
    E.1.1.1Medical condition in easily understood language
    Human Immunodeficiency Virus (HIV-1) Infection
    Infección por el Virus de Inmunodeficiencia Humana (VIH-1)
    E.1.1.2Therapeutic area Diseases [C] - Virus Diseases [C02]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 18.1
    E.1.2Level LLT
    E.1.2Classification code 10068341
    E.1.2Term HIV-1 infection
    E.1.2System Organ Class 100000004862
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the efficacy of switching from a regimen of DTG and ABC/3TC or a fixed dose combination (FDC) of ABC/DTG/3TC to a FDC of
    GS-9883/F/TAF versus continuing DTG and ABC/3TC as the FDC ABC/DTG/3TC in virologically suppressed HIV-1 infected subjects as determined by the proportion of subjects with virologic failure (HIV-1 RNA >= 50 copies/mL) at Week 48.
    Evaluar la eficacia del cambio de un régimen formado por DTG y ABC/3TC, o una combinación de dosis fijas (CDF) de ABC/DTG/3TC, a una CDF de GS-9883/F/TAF en comparación con el mantenimiento del régimen formado por DTG y ABC/3TC en forma de CDF de ABC/DTG/3TC en sujetos infectados por el VIH-1 con supresión virológica, determinada mediante la proporción de sujetos con fracaso virológico (ARN del VIH-1 >= 50 copias/ml) en la semana 48.
    E.2.2Secondary objectives of the trial
    - To evaluate the safety and tolerability of the two treatment groups through Week 48
    - To evaluate the bone safety of the two treatment groups as determined by the percentage change from baseline in hip and spine bone mineral density (BMD) through Week 48
    -Evaluar la seguridad y la tolerabilidad en los dos grupos de tratamiento hasta la semana 48.
    -valuar la seguridad ósea en los dos grupos de tratamiento mediante la variación porcentual de la densidad mineral ósea (DMO) de la cadera y la columna vertebral entre el momento basal y la semana 48
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. The ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures.
    2. Age >= 18 years.
    3. Currently receiving an antiretroviral regimen of DTG + ABC/3TC, or ABC/DTG/3TC FDC for >= 3 months prior to the screening visit.
    4. HIV RNA < 50 copies/mL at the screening visit.
    5. Normal ECG (or if abnormal, determined by the Investigator to be not clinically significant).
    6. Adequate renal function:
    Estimated glomerular filtration rate >= 50 mL/min (>= 0.83 mL/sec) according to the Cockcroft-Gault formula.
    7. Hepatic transaminases (AST and ALT) <= 5 x upper limit of normal (ULN).
    8. Total bilirubin <= 1.5 mg/dL (<= 26 umol/L), or normal direct bilirubin.
    9. Adequate hematologic function (absolute neutrophil count >= 750/mm3 (>= 0.75 GI/L);
    platelets >= 50,000/mm3 (>= 50 GI/L); hemoglobin >= 8.5 g/dL (>= 85 g/L))
    10. Serum amylase <= 5 × ULN (subjects with serum amylase > 5 × ULN will remain eligible if
    serum lipase is <= 5 × ULN).
    11. Females of childbearing potential must agree to utilize protocol recommended highly
    effective contraceptive methods or be non-heterosexually active or practice sexual abstinence
    from screening, throughout the duration of the study period, and for 30 days following the last dose of study drug.
    a) Female subjects who utilize hormonal contraceptive as one of their birth control methods
    must have used the same method for at least 3 months prior to study drug dosing.
    12. Male subjects who engage in heterosexual intercourse must agree to use protocol specified
    method(s) of contraception throughout the study period and for 90 days following the last dose of study drug.
    13. Male subjects must agree to refrain from sperm donation from first study drug dose until at
    least 90 days following the last study drug dose.
    14. Life expectancy >= 1 year.
    15. Currently on the first or second antiretroviral regimen with documented plasma HIV-1 RNA
    < 50 copies/mL on a stable regimen (or undetectable HIV-1 RNA level according to the local
    assay being used if the limit of detection is >= 50 copies/mL) for >= 3 months preceding the
    Screening visit.
    Prior changes in antiretroviral regimen are only allowed due to tolerability issues or for
    regimen simplification. Unconfirmed virologic elevations of >= 50 copies/mL (transient
    detectable viremia, or blip) prior to screening are acceptable. If the lower limit of detection
    of the local HIV-1 RNA assay is <50 copies/mL (eg, <20 copies/mL), the plasma HIV-1
    RNA level cannot exceed 50 copies/mL on two consecutive HIV-1 RNA tests.
    16. Have no documented or suspected resistance to FTC, TFV, DTG, ABC or 3TC including, but
    not limited, to the reverse transcriptase resistance mutations K65R and M184V/I.
    1) Capacidad de entender y firmar el documento de consentimiento informado, que deberá obtenerse antes del inicio de los procedimientos del estudio.
    2) Edad >= 18 años.
    3) Estar recibiendo actualmente una pauta antirretroviral formada por DTG + ABC/3TC, o la CDF de ABC/DTG/3TC, desde al menos 3 meses antes de la visita de selección.
    4) ARN del VIH < 50 copias/ml en la visita de selección.
    5) ECG normal (o, si no lo es, el investigador ha determinado que carece de importancia clínica).
    6) Función renal adecuada:
    Filtración glomerular estimada >= 50 ml/min (>= 0,83 ml/s) según la fórmula de Cockcroft-Gault
    7) Transaminasas hepáticas (ALT y AST) <= 5 x límite superior de la normalidad (LSN).

    8) Bilirrubina total <= 1,5 mg/dl (<= 26 umol/l) o bilirrubina directa normal.


    9) Función hematológica adecuada (recuento absoluto de neutrófilos >= 750/mm3 (>= 0,75 GI/l); plaquetas >= 50.000/mm3 (>= 50 GI/l); hemoglobina >= 8.5 g/dl ( >= 85 g/l).
    10) Amilasa sérica <= 5 veces el LSN (los sujetos con amilasa sérica > 5 veces el LSN seguirán siendo elegibles si la lipasa sérica es <=5 veces el LSN).
    11) Las mujeres en edad fértil deberán comprometerse a utilizar métodos anticonceptivos de gran eficacia recomendados en el protocolo o no mantener relaciones heterosexuales o practicar la abstinencia sexual desde la selección, durante todo el periodo del estudio y hasta 30 días después de la última dosis del fármaco del estudio.
    a) Las mujeres que utilicen anticonceptivos hormonales deberán haber usado el mismo método durante al menos tres meses antes de la administración del fármaco del estudio.


    12) Los varones que mantengan relaciones heterosexuales deberán comprometerse a utilizar métodos anticonceptivos especificados en el protocolo durante todo el período del estudio y hasta 90 días después de la última dosis del fármaco del estudio.

    13) Los sujetos varones tendrán que comprometerse a no donar semen desde la primera dosis del fármaco del estudio y hasta 90 días después, como mínimo, de la última dosis.
    14) Esperanza de vida >= 1 año.
    15) Estar recibiendo actualmente el primer o segundo régimen antirretroviral y tener documentada una concentración plasmática de ARN del VIH-1 < 50 copias/ml (o indetectable conforme al análisis local utilizado si el límite de detección es >= 50 copias/ml) con un régimen estable durante al menos 3 meses antes de la visita de selección.
    Solo se permitirán cambios previos en el tratamiento antirretroviral si se efectuaron por problemas de tolerabilidad o con fines de simplificación. Se aceptan elevaciones virológicas sin confirmar >= 50 copias/ml (viremia detectable transitoria o blip) antes de la selección. Si el límite inferior de detección del análisis local del ARN del VIH-1 es < 50 copias/ml (por ejemplo, < 20 copias/ml), la concentración plasmática de ARN del VIH-1 no podrá superar las 50 copias/ml en dos determinaciones consecutivas del ARN del VIH-1.
    16) Ausencia de resistencia, confirmada o presunta, a FTC, TFV, DTG, ABC o 3TC, como la presencia de las mutaciones K65R y M184V/I de la transcriptasa inversa asociadas a resistencia, entre otras.
    E.4Principal exclusion criteria
    1) An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior to screening
    2) Subjects experiencing decompensated cirrhosis (e.g, ascites, encephalopathy, or variceal bleeding)
    3) Have been treated with immunosuppressant therapies or chemotherapeutic agents within 3 months of study screening, or expected to receive these agents or systemic steroids during the study (e.g, corticosteroids, immunoglobulins, and other immune- or cytokine-based therapies)
    4) Current alcohol or substance use judged by the Investigator to potentially interfere with subject study compliance
    5) A history of or ongoing malignancy (including untreated carcinoma in-situ) other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non-invasive cutaneous squamous carcinoma. Subjects with biopsy-confirmed cutaneous KS are eligible, but must not have received any systemic therapy for KS within 30 days of Day 1 and are not anticipated to require systemic therapy during the study
    6) Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to Day 1
    7) Participation in any other clinical trial, including observational studies, without prior approval from the sponsor is prohibited while participating in this trial
    8) Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the dosing requirements
    9) Any known allergies to the excipients of GS-9883/F/TAF FDC or ABC/DTG/3TC FDC tablets
    10) Females who are pregnant (as confirmed by positive serum pregnancy test)
    11) Females who are breastfeeding
    12) Subjects receiving ongoing therapy with any of the following medications, Dofetilide, Phenobarbital, Phenytoin, Carbamazepine, Oxcarbazepine, Rifampin, Rifapentine, Any antiretroviral drug that is not part of the study regimen,Cisapride, St. John?s Wort, Echinaccea, including drugs not to be used with FTC, TAF, GS-9883, DTG, ABC and 3TC
    13) Acute hepatitis in the 30 days prior to study entry
    14) Chronic Hepatitis B Virus (HBV) infection, as determined by either:
    a) Positive HBV surface antigen and negative HBV surface antibody, regardless of HBV core antibody status, at the screening visit
    b) Positive HBV core antibody and negative HBV surface antibody, regardless of HBV surface antigen status, at the screening visit
    15) Active tuberculosis infection
    1) Enfermedad oportunista indicativa de estadio 3 de la infección por el VIH, diagnosticada en los 30 días previos a la selección

    2) Presencia de cirrosis descompensada (por ejemplo, ascitis, encefalopatía o varices hemorrágicas).
    3) Haber recibido tratamiento con inmunodepresores o quimioterapia en los 3 meses previos a la selección, o tener previsto recibir estos fármacos o esteroides sistémicos durante el estudio (por ejemplo, corticosteroides, inmunoglobulinas y otros tratamientos inmunitarios o basados en citocinas).
    4) Consumo activo de alcohol o sustancias que, según el criterio del investigador, podría afectar al cumplimiento del estudio.
    5) Antecedentes o presencia de una neoplasia maligna (incluido carcinoma in situ no tratado) distinta de un sarcoma de Kaposi (SK) cutáneo, carcinoma basocelular o carcinoma espinocelular cutáneo no invasivo y resecado. Los pacientes con SK cutáneo confirmado mediante biopsia podrán participar, pero no podrán haber recibido un tratamiento sistémico contra el SK en los 30 días previos al día 1 ni se deberá preveer que necesiten tratamiento sistémico durante el estudio.
    6) Infecciones graves activas (aparte de la infección por el VIH-1) que requieran tratamiento parenteral con antibióticos o antifúngicos en los 30 días previos al día 1.
    7) Durante la participación en este estudio queda prohibida la participación en cualquier otro ensayo clínico, incluidos los observacionales, sin la aprobación previa del promotor.
    8) Cualquier otra afección clínica o tratamiento previo que, en opinión del investigador, haga que el sujeto no sea adecuado para el estudio o no sea capaz de cumplir los requisitos de administración.
    9) Alergia a cualquiera de los excipientes de la CDF de GS-9883/F/TAF o de la CDF de ABC/DTG/3TC en comprimidos.

    10) Embarazo (confirmado mediante un resultado positivo en la prueba de embarazo en suero).
    11) Mujeres en período de lactancia.


    12) Tratamiento en curso con alguno de los medicamentos siguientes: Dofetilida, Fenobarbital, fenitoína, Carbamazepina, Oxcarbazepina, Rifampicina, Rifapentina, Todos los antirretrovirales que no formen parte del tratamiento del estudio ,Cisaprida, Hipérico, Equinácea; incluidos los que no deben utilizarse con FTC, TAF, GS-9883, DTG, ABC y 3TC

    13) Hepatitis aguda en los 30 días previos a la entrada en el estudio.
    14) Infección crónica por el virus de la hepatitis B (VHB), determinada por cualquiera de los siguientes:
    a) Resultado positivo para el antígeno de superficie del VHB y negativo para los anticuerpos contra el antígeno de superficie del VHB, con independencia del resultado para los anticuerpos contra el antígeno central del VHB, en la visita de selección.
    b) Resultado positivo para los anticuerpos contra el antígeno central del VHB y negativo para los anticuerpos contra el antígeno de superficie del VHB, con independencia del resultado para el antígeno de superficie del VHB, en la visita de selección.
    15) Infección por tuberculosis activa.
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy endpoint is:
    The proportion of subjects with virologic failure (HIV-1 RNA >= 50 copies/mL) at Week 48 as defined by the modified US FDA snapshot algorithm.
    El criterio principal de valoración de la eficacia es el siguiente:
    Proporción de sujetos con fracaso virológico (ARN del VIH-1 >= 50 copias/ml) en la semana 48 según lo definido mediante el algoritmo de instantáneas de la FDA estadounidense modificado.
    E.5.1.1Timepoint(s) of evaluation of this end point
    At Week 48
    Semana 48
    E.5.2Secondary end point(s)
    The secondary endpoints of this study include:
    - The proportion of subjects with HIV-1 RNA < 50 copies/mL at Week 48 as defined by the US FDA snapshot algorithm.
    - The change from baseline in CD4+ cell count at Week 48
    - The percentage change from baseline in hip and spine BMD at Week 48
    Los criterios de valoración secundarios de este estudio comprenden:
    ? Proporción de sujetos con una concentración de ARN del VIH-1 < 50 copias/ml en la semana 48 según lo definido mediante el algoritmo de instantáneas de la FDA estadounidense.
    ? Variación del recuento de linfocitos CD4+ entre el momento basal y la semana 48.
    ? Variación porcentual de la DMO de la cadera y la columna vertebral entre el momento basal y la semana 48.
    E.5.2.1Timepoint(s) of evaluation of this end point
    At Week 48
    Semana 48
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned8
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA28
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Belgium
    Canada
    France
    Germany
    Italy
    Japan
    Spain
    Sweden
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Última Visita Último Sujeto (UVUS)
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months3
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months7
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 430
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 90
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state18
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 140
    F.4.2.2In the whole clinical trial 520
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    After a subject has completed/terminated their participation in the study, long-term care for the subject will remain the responsibility of their primary treating physician.
    Después de que un paciente haya completado / terminado su participación en el estudio, el cuidado a largo plazo para el paciente seguirá siendo la responsabilidad de su médico de atención primaria.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-03-11
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-02-04
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2019-10-23
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 14:22:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA